维普中文期刊产品整合服务
252篇 您的检索式:作者名="Gulley"
    题名 作者 年代 出处 被引量
1Immunotherapy and therapeutic vaccines in prostate cancer: an update on current strategies and clinical implications显示文摘在最近的年里,免疫疗法为前列腺癌症的治疗作为可行、吸引人的策略出现了。当有指向免疫系统的多重方法时,治疗学的癌症疫苗和有免疫力的检查点禁止者在迟了阶段的临床的试用是很成功的。为无征状或最低限度地征兆的变形前列腺癌症的 sipuleucel-T 的里程碑食物药品管理局赞同与癌症疫苗 PSA 得信佳和有免疫力的检查点禁止者 ipilimumab 为进行中的阶段 III 试用作准备。没有短期的变化,这些基于免疫者的治疗的一个普通特征是改进全面幸存的外观。这类效果看起来由于肿瘤生长率动力学,激活的免疫系统在施加减缓网络肿瘤生长的经常的 immunologic 压力的调整。新兴的数据建议为癌症疫苗的临床的试用的理想的人口是有更低的肿瘤体积和更少的好攻击的疾病的病人。把免疫疗法与标准治疗相结合的联合策略被显示了扩充有免疫力的反应和临床的利益。B Harpreet Singh James L Gulley 2014Asian Journal of Andrology2014,16,3:6
2Perspectives on the clinical development of mmunotherapy in prostate cancer显示文摘Lisa M Cordes James L Gulley Ravi A Madan 2018Asian Journal of Andrology2018,20,3:2
3A randomized phase Ⅱ study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer显示文摘Arlen PM Gulley JL Parker C 2006Clin Cancer Res2006,12,4:1
4A randomized phase II trim of docetaxel ( taxotere ) plus thalidomide in androgen-independent prostate cancer 显示文摘Figg WD Aden P Gulley J 2001Semin Oncol2001,28,415:1
5Standard mutation no- menclature in molecular diagnostics: practical and educational chal- lenges显示文摘Ogino S Gulley ML den Dunnen JT 2007J Mol Diagn2007,9,1:1
6Nasopharyngeal carcinomas frequently lack the P16/MTS1 tumor suppressor protein but consistently express the retinoblastoma gene product 显示文摘 Nivholls JM Schneider BG 1998Am J Pathol1998,152,4:1
7Significant prostate - spe- cific antigen (PSA) response to low - dose ketoconazole in a patient with non - metastatic androgen - independent prostate cancer ( AIPC ) and a review of the literature显示文摘Madan RA Lieberman R Gulley JL 2007Am J Ther2007,14,3:1
8Laboratory Assays for Epstein-Barr Virus-Related Disease 显示文摘Margaret L Gulley Weihua Tang 2008JMD2008,4,:1
9Epstein -Ban- virus infection is an early event in gastric carcinogenesis and in independent of bcl -2 expression and p53 accumulation显示文摘Gulley ML Pulitzer DR Eagan PA 1996Hum Pathol1996,27,1:1
10A phase Ⅱ study of perifosine in androgen independent prostate cancer 显示文摘Posadas E M Gulley J Arlen P M 2005Cancer Biol Ther2005,4,10:1
11Induction of mucosal immunity in the avian Harderian gland with a replication-deficient Ad5 vector expressing avian influenza H5 hemagglutinin显示文摘Frederik W. van Ginkel De-chu C. Tang Stephen L. Gulley Haroldo Toro 2008Developmental and Comparative Immunology2008,,1:1
12Standard mutation nomenclature in molecular diagnostics: Practical and educational challenges显示文摘Ogino S Gulley ML den Dunnen JT 2007J Mol Diagn2007,9,1:1
13Infec tious Bronchitis Virus In The Chicken Harderian Gland and Lachrymal Fluid: Viral Load, Infectivity, Immune Cell Re- sponses, and Effects of Viral Immunodeficiency显示文摘Van Ginkel F W Van Santen V L Gulley S L 2008Summa rized from Avian Diseases2008,52,60:1
14Randomized phase Ⅱ trial of docetaxel plus thalidomide in androgen-independent prostate cancer显示文摘Dabut WL Gulley JL Arlen PM 2004J Clin Oncol2004,22,13:1
15The role of soluble CD40L in immunosuppression显示文摘Schlom J Jochems C Gulley JL 2013Oncoimmunol2013,2,1:1
16Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors 显示文摘Dahut WL Lakhani NJ Gulley JL 2006Cancer Biol Ther2006,5,1:1
17EpsteinBarr virus is associated with p53 accumulation in nasopharyngeal carcinoma显示文摘GULLEY ML BURTON MP ALLRED DC 1998Hum Pathol1998,29,:1
18Phase II trial ofbevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer显示文摘Ning YM Gulley JL Arlen PM 2010J Clin Oncol2010,2028,12:1
19Guidelines for interpreting EBER in situ hybridization and LMPI immunohistochemical tests for detecting Epstein-Barr virus in Hodgkin lymphoma显示文摘Gulley ML Glaser SL Craig FE 2002AmJ Clin Pathol2002,117,2:1
20Consumer Confidence Announcements:do they Matter显示文摘Gulley O Sultan J 0,,02:1
返回顶部 每页显示:
共13页 首页 上一页 第1页 下一页 末页 /13 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费